Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion in Psychedelic Drug Development
Eli Lilly announced its acquisition of clinical-stage psychedelic drug developer AtaiBeckley for up to $3.8 billion, signaling growing interest from Big Pharma in treating mental health conditions with psychedelics. This follows positive trial results and regulatory support under President Trump's executive order accelerating FDA reviews.
Topics: mental health drugs pharma psychedelics